Unknown

Dataset Information

0

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.


ABSTRACT: Tamoxifen is the standard first-line hormonal therapy for premenopausal women with estrogen receptor (ER)-positive metastatic breast cancer (BC). One of the crucial mechanisms underlying hormonal therapy resistance is the collateral activation of the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. We explored whether PI3K inhibitors, buparlisib and alpelisib, enhance the efficacy of tamoxifen against ER-positive BC cells. We have observed a synergism between alpelisib or buparlisib and tamoxifen in the treatment for ER-positive BC cell lines harboring different PI3K alterations. Immunoblotting analysis showed alpelisib, buparlisib, or either drug in combination with tamoxifen downregulated the PI3K downstream targets in the MCF-7 and ZR75-1 cells. In the MCF-7 cells transfected with a constitutive active (myristoylated) AKT1 construct or mutant ER, the synergistic effect between alpelisib and tamoxifen was markedly attenuated, indicating that synergism depends on AKT inhibition or normally functioning ER. Combining alpelisib or buparlisib with tamoxifen also attenuated MCF-7 tumor growth in Balb/c nude mice. Our data suggest that additional PI3K blockade might be effective in enhancing the therapeutic effect of tamoxifen in ER-positive BC and support the rationale combination in clinical trials.

SUBMITTER: Chen IC 

PROVIDER: S-EPMC5574981 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.

Chen I-Chun IC   Chen I-Chun IC   Hsiao Li-Ping LP   Huang I-Wen IW   Yu Huei-Chieh HC   Yeh Ling-Chun LC   Lin Ching-Hung CH   Wei-Wu Chen Tom T   Cheng Ann-Lii AL   Lu Yen-Shen YS  

Scientific reports 20170829 1


Tamoxifen is the standard first-line hormonal therapy for premenopausal women with estrogen receptor (ER)-positive metastatic breast cancer (BC). One of the crucial mechanisms underlying hormonal therapy resistance is the collateral activation of the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. We explored whether PI3K inhibitors, buparlisib and alpelisib, enhance the efficacy of tamoxifen against ER-positive BC cells. We have observed a synergism between alpelisib or buparlisib and tamoxif  ...[more]

Similar Datasets

| S-EPMC5892720 | biostudies-literature
| S-EPMC6454890 | biostudies-literature
| S-EPMC3219179 | biostudies-literature
| S-EPMC2898598 | biostudies-literature
2015-08-21 | PXD000484 | Pride
2015-08-21 | PXD000485 | Pride
| S-EPMC5847064 | biostudies-literature
| S-EPMC4854767 | biostudies-literature
| S-EPMC2423197 | biostudies-literature
| S-EPMC10103953 | biostudies-literature